Celgene Corporation Release: Apremilast Achieves Statistical Significance for the Primary and Major Secondary Endpoints in Fourth Pivotal Phase III Study (PALACE 4) of Patients With Psoriatic Arthritis

Posted: May 7th, 2013  |  Company/topic: Celgene
Website: BioSpace.com Featured News
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Srl, a subsidiary of Celgene Corporation (NASDAQ:…
Tags: , ,

Concert Pharmaceuticals, Celgene to develop deuterium-modified compounds

Posted: May 7th, 2013  |  Company/topic: Celgene
Website: PBR - Contract Research News
Concert Pharmaceuticals and Celgene Corporation have entered into strategic collaboration to direct deuterium-modified compounds targeting cancer and inflammation.
Tags: , ,

Celgene signs Concert pact, apremilast impresses for PsA

Posted: May 7th, 2013  |  Company/topic: Celgene
Website: PharmaTimes World News
Celgene signs Concert pact, apremilast impresses for PsA…
Tags: , ,

Concert Pharmaceuticals, Celgene to develop deuterium-modified compounds

Posted: May 7th, 2013  |  Company/topic: Celgene
Website: CenterWatch News Online Headlines
Concert Pharmaceuticals, a clinical stage biotechnology company, has entered into a strategic collaboration with Celgene, a Summit, N.J.-based integrated global biopharmaceutical company, directed tow…
Tags: , ,